咨询订购

点击这里给我发消息
Welcome to Raystarbio!Focus On Forefront Bioactive Compounds.
Find Your Distributors

Select Your Country or Region

$ USD

You are here:Home-Research Areas-Other Indications-Ulcer

Request The Product List ofUlcer Ulcer

    Ulcer, a lesion or sore on the skin or mucous membrane resulting from the gradual disintegration of surface epithelial tissue. An ulcer may be superficial, or it may extend into the deeper layer of the skin or other underlying tissue. An ulcer has a depressed floor or crater surrounded by sharply defined edges that are sometimes elevated above the level of the adjoining surface. The main symptom of an ulcer is pain.

   The main causes of ulcers are infection, faulty blood circulation, nerve damage, trauma, nutritional disturbances including thiamine or other vitamin deficiencies, and cancer. Such bacterial infections as tuberculosis or syphilis can cause ulcers on any surface of the body. Any infection under the skin, such as a boil or carbuncle, may break through the surface and form an inflammatory ulcer. The ulcers on the legs of persons with varicose veins are caused by the slow circulation of the blood in the skin. Diabetics may sustain ulcers on their feet or toes after losing sensation in those areas due to nervous-system damage. A bedsore, or decubitus ulcer, typically occurs on the skin of the back in immobilized or bedridden persons. A peptic ulcer is an ulcer that occurs in the stomach or the first segment of the duodenum, parts of the intestinal tract that are bathed by gastric juice. Ulcers can also result from burns, electric burns, and frostbite.


    When an ulcer of the skin does not heal or is hard to the touch, the possibility of cancer must be considered. The probability of cancer is increased if the patient is past middle age. Ulcers on the border of the lower lip in elderly men are frequently cancers. Such cancers must be recognized and treated early before they spread and become inoperable. By contrast, superficial ulcers on the lips, known as cold sores, are caused by a virus and are not serious. Ulcers in the mouth and throat are frequently caused by infection but are sometimes cancerous, especially in older persons. Cancerous ulcers may also occur in the stomach, small or large intestine, and rectum.



Cat. No. Product Name CAS No. Information
GY07080

PH-46A N-Methyl-D-Glucamine salt

1380445-04-4

PH-46A is a potent, first-in-class, oral small-molecule agent for the treatment of inflammatory bowel diseases.

GY07079

PH-46A

1421332-97-9

PH-46A is a potent, first-in-class, oral small-molecule agent for the treatment of inflammatory bowel diseases.

GY06627

GLPG 0974

1391076-61-1

GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM; inhibits acetate-induced neutrophil migration strongly in vitro with IC50 of 27 nM; demonstrates ability to inhibit a neutrophil-based pharmacodynamic (PD) marker, CD11b activation-specific epitope [AE], in a human whole blood assay.

GY05234

Revaprazan hydrochloride

178307-42-1

Revaprazan (SB-641257;YH-1885) potent potassium-competitive acid blocker (P-CAB) that inhibits H+,K+-ATPase in a reversible and K+-competitive manner; reduces gastric acid secretion, also exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling.

GY05208

Revaprazan

199463-33-7

Revaprazan (SB-641257;YH-1885) is a potent potassium-competitive acid blocker (P-CAB) that inhibits H+,K+-ATPase in a reversible and K+-competitive manner; reduces gastric acid secretion, also exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling.

GY05322

TAK-438

1260141-27-2

A novel potent, potassium-competitive acid blocker (P-CAB) that inhibits H(+),K(+)-ATPase activity in porcine gastric microsomes with IC50 of 19 nM at pH 6.5; the inhibitory activity of TAK-438 is unaffected by ambient pH, but not SCH28080 and lansoprazole; completely inhibits basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats at 4 mg/kg (as the free base) orally; a more potent and longer-lasting inhibitory action on gastric acid secretion than either lansoprazole or SCH28080.

GY05167

CS-526

313272-12-7

CS-526 (AKU 517;R 105266) is a potent, competitive, and reversible acid pump antagonist (potassium-competitive acid blocker) that inhibits H+,K+-ATPase activity with IC50 of 61 nM; inhibits gastric acid secretion in pylorus-ligated rats with ID50 of 0.7 mg/kg (p.o.); inhibits histamine-stimulated gastric acid secretion in Heidenhain pouch dogs, inhibits acute gastric mucosal lesions and has potent antisecretory and antiulcer effects.

GY05056

Tegoprazan

942195-55-3

A novel potent, highly selective, competitive and orally active inhibitor of gastric H+/K+-ATPase with IC50 of ranging 0.29-0.52 uM porcine, canine and human H+/K+-ATPases in vitro; displays no activity against canine kidney Na+/K+-ATPase (IC50>100 uM); potently inhibits histamine-induced gastric acid secretion in dogs and a complete inhibition at 1.0 mg/kg starting from 1 hr after administration, reverses the pentagastrin-induced acidified gastric pH to the neutral range at 1-3 mg/kg, immediately evoks a gastric phase III contraction of migrating motor complex (MMC) in pentagastrin-treated dogs.

GY03091

AZD-0865

248919-64-4

AZD-0865 is a potent, selective acid pump antagonist (potassium-competitive acid blocker or P-CAB) that reversiblely inhibits gastric H+/K+-ATPase with pIC50 of 6.5; inhibits H+/K+-ATPase activity in a K(+)-competitive manner with Ki of 46 nM, shows no ativity for porcine renal Na(+),K(+)-ATPase at 100 uM; inhibits gastric acid secretion in vivo.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 RayStarBio. All Rights Reserved. Products are only for research use